Information Provided By: 
Fly News Breaks for August 20, 2019
ANAB
Aug 20, 2019 | 07:53 EDT
After speaking to AnaptysBio management, Cantor Fitzgerald analyst Eliana Merle said she thinks the resignation of CFO Dominic Piscitelli likely has no read-through to the company's ongoing clinical studies, which all remain blinded. While "optically this timing might not be ideal," management reiterated that all clinical timelines remain on track and her sense is that Piscitelli was approached with a compelling opportunity, the analyst tells investors. Merle keeps an Overweight rating on AnaptysBio shares with a $140 price target.
News For ANAB From the Last 2 Days
There are no results for your query ANAB
